How BRCA1 Loss Disables Homologous Recombination and Creates PARP Inhibitor Sensitivity

The ATM–BRCA1 Signalling Cascade at DNA Double-Strand Breaks

When a DNA double-strand break (DSB) is detected by the MRN complex (MRE11–RAD50–NBS1), ATM kinase is rapidly activated and phosphorylates histone H2AX (γH2AX) across megabase chromatin domains flanking the break. ATM directly phosphorylates BRCA1 at Ser1387 and Ser1423 (within the BRCT domain), enabling BRCA1's recruitment to break sites via the γH2AX→MDC1→RNF8/RNF168→ubiquitin-H2A→RAP80/ABRAXAS pathway. This ATM→BRCA1 signalling axis is the first step in the homologous recombination cascade and the molecular foundation of BRCA1 tumour suppression.

ATM also phosphorylates CHK2 (Thr68), which then phosphorylates BRCA1 at Ser988 — providing a second kinase input reinforcing BRCA1 activation. This redundant ATM→BRCA1 and ATM→CHK2→BRCA1 signalling ensures robust BRCA1 recruitment even in the context of partial ATM loss. Germline BRCA1 mutations that disrupt the BRCT domain (which contains the BRCA1 phosphoserine-binding motifs and is the most commonly mutated region in BRCA1-associated cancer) specifically abrogate this ATM-mediated recruitment — connecting loss of BRCA1 HR function directly to the failure of upstream ATM signalling to engage the repair cascade.

Homologous Recombination: BRCA1's Core Tumour Suppressor Pathway

At the DSB site, BRCA1 performs two critical functions in the HR cascade. First, BRCA1 promotes DNA end resection — the 5′-to-3′ nucleolytic degradation that generates 3′ single-stranded DNA (ssDNA) overhangs essential for HR — by antagonising the competing 53BP1-RIF1 pathway that otherwise directs breaks toward non-homologous end joining (NHEJ). Second, BRCA1 recruits BRCA2 to the break site through its interaction with PALB2 via the BRCA1 coiled-coil domain; BRCA2 then loads RAD51 recombinase onto the RPA-coated 3′ ssDNA, enabling strand invasion into the intact sister chromatid template for high-fidelity repair.

Loss of BRCA1 function forces cells to rely on error-prone repair pathways — NHEJ (which can rejoin DSBs with deletions at the junction), microhomology-mediated end joining (MMEJ), and single-strand annealing (SSA) — that introduce deletions, insertions, and translocations. Over time, this 'BRCAness' phenotype generates a characteristic pattern of genomic scarring: large deletions, tandem duplications, and balanced translocations detectable by homologous recombination deficiency (HRD) scoring. HRD score ≥42 (Foundation Medicine/Myriad HRD assay) is used clinically to identify tumours with HR deficiency beyond germline BRCA1/2 carriers.

PARP Inhibitor Synthetic Lethality: Exploiting the Homologous Recombination Defect

The therapeutic exploitation of BRCA1 loss rests on synthetic lethality: simultaneous disruption of two cellular repair pathways that are individually survivable but lethal in combination. BRCA1-deficient cancer cells cannot perform HR, relying on PARP1-mediated single-strand break (SSB) repair as their primary backup for replication-associated DNA damage. PARP inhibitors (olaparib, niraparib, rucaparib, talazoparib) trap PARP1 on DNA as stable covalent PARP-DNA complexes at SSB sites rather than allowing catalytic release after repair.

When a replication fork collides with a trapped PARP1-DNA complex, it collapses into a DSB. In HR-proficient normal cells, this replication-associated DSB is accurately repaired using the BRCA1→BRCA2→RAD51 homologous recombination pathway. In BRCA1-deficient cancer cells, the DSB cannot be repaired by HR and error-prone pathways accumulate lethal chromosomal damage selectively in the cancer cells. This selective lethality underpins PARP inhibitor approvals across BRCA1/2-mutant breast (talazoparib, olaparib), ovarian (all four PARP inhibitors), pancreatic (olaparib), and prostate (olaparib, rucaparib) cancers — one of the broadest multi-tumour applications of a single synthetic lethality concept.

Surveillance, Risk Reduction, and Clinical Management

BRCA1 mutation carriers require enhanced surveillance beginning at age 25–30: annual breast MRI (superior to mammography for dense breast tissue and young carriers), with annual mammography added from age 30. Gynaecological surveillance for ovarian cancer is less effective — transvaginal ultrasound and CA-125 monitoring have limited sensitivity for early ovarian cancer — explaining why risk-reducing salpingo-oophorectomy (RRSO) by age 35–40 is recommended to reduce ovarian cancer mortality by ~80%.

Chemoprevention with tamoxifen reduces breast cancer risk by ~40% in BRCA1/2 carriers, though BRCA1-associated tumours are commonly ER-negative, limiting tamoxifen benefit specifically for BRCA1. Risk-reducing mastectomy reduces breast cancer risk by ~95% and is offered to carriers who have completed breast surveillance or who prefer definitive risk reduction. Cascade testing of first-degree relatives after a proband's diagnosis is essential and cost-effective.

BRCA1 vs BRCA2: Distinct Roles, Different Cancer Spectrums

Although both BRCA1 and BRCA2 are essential for homologous recombination, they act at different steps. BRCA1 functions upstream: it promotes DSB end resection to generate 3′ ssDNA overhangs (by antagonising 53BP1-mediated NHEJ) and recruits BRCA2 to the break site through its interaction with PALB2 via a coiled-coil domain. BRCA2 functions downstream: it directly loads RAD51 onto RPA-coated 3′ ssDNA overhangs through its eight BRC repeats and a C-terminal RAD51-binding domain, enabling strand invasion and template-directed repair. Loss of either protein impairs HR, but at mechanistically distinct steps.

Their cancer spectrums reflect these molecular roles. BRCA1 mutations predominantly predispose to triple-negative breast cancer (TNBC) — approximately 70–80% of BRCA1-associated breast cancers are ER/PR/HER2-negative, compared to ~15% in the general population — and to high-grade serous ovarian cancer. BRCA2 mutations predispose to ER-positive breast cancer more similar to sporadic disease, a substantially higher male breast cancer risk (~7% lifetime vs 0.1% general male population), and pancreatic cancer risk (~5–7% lifetime). Germline BRCA2 mutations also occur in ~5% of prostate cancers and confer more aggressive disease biology, explaining why BRCA2 testing is now standard in advanced prostate cancer.

BRCA1 in Triple-Negative Breast Cancer and Platinum Sensitivity

TNBC is the most clinically challenging breast cancer subtype, characterised by high proliferative rate, early visceral metastasis, and absence of targetable hormone receptors or HER2 amplification — leaving chemotherapy as the principal systemic option for most patients. Germline BRCA1 mutations account for ~15–20% of TNBC, and somatic BRCA1 promoter methylation or mutation accounts for an additional ~10–15%, creating a substantial 'BRCAness' subset with HR deficiency beyond germline carriers. BRCA1-mutant TNBC has high homologous recombination deficiency (HRD) scores and characteristic genomic scarring patterns (large deletions, tandem duplications) that serve as biomarkers of HR deficiency.

The OlympiA trial demonstrated that adjuvant olaparib for 1 year in germline BRCA1/2-mutant HER2-negative early breast cancer improved 4-year invasive disease-free survival from 77.1% to 82.7% (HR 0.63, p<0.001) — now standard of care for high-risk BRCA1/2-mutant early breast cancer. In the metastatic setting, talazoparib (OlympiAD equivalent, EMBRACA trial: 8.6 vs 5.6 months PFS) and olaparib (OlympiAD trial: 7.0 vs 4.2 months PFS) are approved for germline BRCA1/2-mutant HER2-negative metastatic breast cancer, establishing PARP inhibition as the targeted therapy of choice for this population.

Key Takeaways

• ·ATM kinase is activated within seconds of DSB detection and directly phosphorylates BRCA1 (Ser1387/1423), initiating the ATM→BRCA1 signalling cascade. BRCA1 then orchestrates homologous recombination upstream — promoting DSB end resection and recruiting BRCA2 via PALB2 — while BRCA2 acts downstream, directly loading RAD51 onto ssDNA for strand invasion.
• ·Germline BRCA1 mutations confer ~50–70% lifetime breast cancer risk (predominantly TNBC) and ~40–45% ovarian cancer risk; BRCA2 mutations confer ER+ breast, pancreatic, prostate, and male breast cancer predisposition.
• ·PARP inhibitor synthetic lethality exploits BRCA1-deficient cells' dependence on PARP1-mediated SSB repair — PARP trapping converts SSBs to DSBs at replication forks, which cannot be repaired by HR-deficient cells.
• ·Adjuvant olaparib (OlympiA trial) reduces invasive disease-free survival events by 37% (HR 0.63) in high-risk germline BRCA1/2-mutant early breast cancer — now standard adjuvant care for this population.
• ·Risk-reducing salpingo-oophorectomy by age 35–40 in BRCA1 carriers reduces ovarian cancer mortality by ~80% and is the most effective risk-reduction intervention given the poor sensitivity of ovarian cancer screening.